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Abstract
Background: Limb-girdle muscular dystrophy (LGMD) is a group of heterogeneous muscular
disorders with autosomal dominant and recessive inheritance, in which the pelvic or shoulder girdle
musculature is predominantly or primarily involved. Although analysis of the defective proteins has
shed some light onto their functions implicated in the etiology of LGMD, our understanding of the
molecular mechanisms underlying muscular dystrophy remains incomplete.
Methods: To give insight into the molecular mechanisms of AR-LGMD, we have examined the
differentially expressed gene profiling between the relative normal and pathological skeletal
muscles from the same AR-LGMD patient with the differential display RT-PCR approach. The
research subjects came from a Chinese AR-LGMD family with three affected sisters.
Results: In this report, we have identified 31 known genes and 12 unknown ESTs, which were
differentially expressed between the relative normal and dystrophic muscle from the same LGMD
patient. The expression of many genes encoding structural proteins of skeletal muscle fibers (such
as titin, myosin heavy and light chains, and nebulin) were dramatically down-regulated in dystrophic
muscles compared to the relative normal muscles. The genes, reticulocalbin 1, kinectin 1, fatty acid
desaturase 1, insulin-like growth factor binding protein 5 (IGFBP5), Nedd4 family interacting
protein 1 (NDFIP1), SMARCA2 (SWI/SNF related, matrix associated, actin dependent regulator of
chromatin, subfamily a, member 2), encoding the proteins involved in signal transduction and gene
expression regulation were up-regulated in the dystrophic muscles.
Conclusion: The functional analysis of these expression-altered genes in the pathogenesis of
LGMD could provide additional information for understanding possible molecular mechanisms of
LGMD development.
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Background
The limb-girdle muscular dystrophies (LGMDs) are a
group of clinically and genetically heterogeneous disor-
ders of the skeletal muscle inherited in either autosomal
dominant or recessive fashion. LGMDs are characterized
clinically by progressive muscle weakness predominantly
in the pelvic and shoulder-girdle muscles, serum creatine
kinase (SCK) elevation, normal intelligence and great var-
iability, ranging from severe forms with onset in the first
decade and rapid progression to milder forms with later
onset and a slower course [1,2]. The diagnosis of LGMDs
can be excluded by the finding of severely abnormal dys-
trophin staining on muscle biopsies [3].
Autosomal dominant LGMD, named LGMD1/AD-
LGMD, contains at least six entities designated LGMD1A
to 1F [4-7]. Gene mutations of myotilin, laminA/C or
caveolin3 can lead to LGMD1A-1C. The candidate genes
for three other types of LGMD1 have not been identified.
There are at least ten distinct entities of autosomal reces-
sive LGMD, designated LGMD2/AR-LGMD (LGMD2A to
LGMD2J), and a number of genes and their mutations
involved in the pathogenesis of LGMD2 have been well-
documented [8]. The identification of the gene mutations
and protein products involved in the LGMDs provide an
avenue to the molecular diagnosis of LGMDs.
Although analysis of the defective proteins has shed some
light onto their functions implicated in the etiology of
LGMD, our understanding of the molecular mechanisms
underlying muscular dystrophy remains incomplete. We
still do not know why the different defective proteins can
cause the same clinical manifestations, such as muscle
weakness and dystrophy, during the disease development.
From our current understanding of LGMD development,
it seems most likely that many regulatory genes that par-
ticipate in muscular pathogenesis have not been identi-
fied. Thus, one of the remaining challenges in
understanding the molecular basis of LGMDs is to iden-
tify those regulatory genes that play very important roles
in the LGMD pathogenesis. Toward this end, gene expres-
sion profiling alterations in LGMD patients, as compared
to the normal person, have been reported [9-11].
To contribute to the identification of additional regula-
tory genes involved in the muscle pathogenesis of AR-
LGMD, differential display reverse transcription polymer-
ase chain reactions (DD-RT-PCR) have been used to com-
pare the gene expression differences between the relative
normal and pathological dystrophic skeletal muscles from
the same LGMD patient. The muscle samples taken from
the same patients in this study could reduce the genetic
background resulting from the comparison between two
different people (one normal and one patient). We have
identified 43 differentially expressed genes (31 known
genes and 12 new ESTs) between the normal and dys-
trophic muscles from the same LGMD patient. Expression
analyses of those genes indicated that expression of the
genes encoding structural proteins of skeletal muscle fib-
ers were significantly down-regulated in dystrophic mus-
cles compared to the relative normal muscles from the
same patients. However, the genes encoding the proteins
participating in signal transduction and expression regula-
tion were up-regulated in the dystrophic muscles of the
same patients. The further functional analyses of these
genes in the pathogenesis of LGMD would be of great
interest for the better understanding of the molecular
mechanisms of LGMD development.
Methods
Patients and clinical diagnosis
The patients were out patients from the Department of
Neurology of the Second Hospital of Harbin Medical Uni-
versity, Harbin, China. The AR-LGMD patients were diag-
nosed according to clinical observations, family history,
serum creatine kinase (SCK) levels, electromyography
(EMG) features and normal dystrophin and emerin
expression. Muscle biopsies (quadriceps and deltoids)
were obtained with informed consent following protocols
based on the institutions.
Total RNA isolation and DNase treatment
Total RNA was isolated from muscle biopsies using the
Trizol reagent (Invitrogen) according to the manufac-
turer's instructions. Genomic DNA contamination was
removed by DNase I digestion at 37°C for 30~40 min.
The DNase-treated RNAs were extracted with phenol/
chloroform and precipitated with ethanol.
Reverse transcription for the first-strand cDNA synthesis
Three reverse transcription reactions, each containing one
of the three different anchored primers, were performed
for each RNA sample. The DNase treated total RNA (1 μg)
was used as the template for each reverse transcription
reaction. The reactions were carried out according to the
protocols of Advantage RT-for-PCR Kit (Clontech). The
anchored primers used in these experiments were synthe-
sized by the Shanghai Sangon Corporation, including
B0327: 5'-AAGCTTTTTTTTTTG-3', B0328: 5'-
AAGCTTTTTTTTTTA-3', B0329: 5'-AAGCTTTTTTTTTTC-3'.
mRNA differential display
The mRNA differential display (DD-PCR) was performed
with a modification of the procedure described by Liang
and Pardee [24]. The double-stranded cDNA was synthe-
sized with combinations of arbitrary primers and
anchored primers in the presence of the isotope [α-33P]
dATP. The arbitrary primers used in this experiment were
synthesized by the Shanghai Sangon Corporation, includ-
ing B0305:5'-GGAACCAATC-3', B0306:5'-AAACTC-Journal of Translational Medicine 2006, 4:53 http://www.translational-medicine.com/content/4/1/53
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CGTC-3', B0307:5'-TCGATACAGG-3', B0308:5'-
TGGTAAAGGG-3', B0309:5'-TCGGTCATAG-3', B0310:5'-
GGTACATTGG-3', B0311:5'-TACCTAAGCG-3', B0312:5'-
CTGCTTGATG-3', B0313:5'-GTTTTCGCAG-3', B0314:5'-
GATCAAGTCC-3'. The PCR reactions contained 1 μl of
reverse transcriptional products, 0.2 μl [α-33P] dATP(10
mCi/ml, NEN), ExTaq 1.25U (Takara), 2.0 μmol/L
anchored primer, 0.5 μmol/L arbitrary primer and 2.0
μmol/L dNTPs. The PCR was performed under the follow-
ing conditions: 94°C for 3 min and then 35 cycles of
94°C for 30 s, 40°C for 2 min, and 72°C for 1 min. A final
extension was carried out at 72°C for 5 min. The PCR
products were separated on 6% denaturing polyacryla-
mide gels at 60 watt for 6 hours. The gel was dried and
DNA bands were visualized by autoradiography at -80°C.
Re-amplification, cloning and sequencing of differentially 
expressed cDNA fragments
The differential bands were excised from the gel, and DNA
was eluted by boiling the gel in 100 μl of H2O for 15 min
and then precipitated at -70°C for at least 30 min with 10
μl of 3M NaAc, 5 μl of glycogen (20 mg/ml) and 400 μl of
100% ethanol. Precipitated DNA was washed once with
85% ethanol, dissolved in 10 μl of H2O and used as the
template to re-amplify the fragment by PCR with the same
primer set and conditions used for the above DD-PCR
reaction. The gel-purified DNA was ligated to pGEM®-T
Easy vector system (Promega) and sequenced. The
sequences were analyzed with the BLASTN program.
Real time qRT-PCR
PCR analyses were performed using the ABI Prism 7500
System. Real-time quantification employed the SYBR
Green PCR Master Mix (ABI). PCR primers were designed
using AB PRISM Primer Express 2.0 software. To avoid
amplification of contaminating genomic DNA, one of the
two primers was placed at or just outside the exon/exon
junction (see Table 3). BLASTN searches have been done
against sequence databases to confirm gene specificity of
the primer sequences. qRT-PCR was performed in tripli-
cates with standard deviations of threshold cycle (CT) val-
ues not exceeding 0.5. After a general reverse transcription
reaction, PCR analyses were performed in the 20 μl ampli-
fication reactions containing 10 μl of SYBR Green PCR
Master Mix, 20 ng cDNA and 0.5 μM of each primer at the
following conditions: 95°C for 10 minutes × 1 cycle, 40
cycles at 95°C for 15 seconds and then at 60°C for 1
minute. At the end of the PCR, the results were exported
to Microsoft Excel for analysis.
RT-PCR detection
The primers were designed according to the sequences of
the six new ESTs. The sense primer for A1 was 5'-CATT-
GAGGGAGCATGTTTAG-3' and the antisense primer was
5'-AGAATATGCAACCAGAAGAG-3'; sense primer for 5A-
C was 5'-GACACAACCTGACAAATGGGATAA-3' and the
antisense primer was 5'-CCTGTTAGCCATT-
TATATATCGTC-3'; the sense primer for 2A-A was 5'-
GAGAAAAATAGAGATCTAAAGAGGG-3', the antisense
primer for 2A-A was 5'-GCATCTGTGACAACATAGTCCT-
GAC-3'; the sense primer for 7B-B was 5'-GATACAG-
GCCAGTGTAGAATTATG-3', the antisense primer was 5'-
GACACCAAATGTCCTGAA CAATCA-3'; the sense primer
for 11A-A was 5'-ATGTTCAGCAACCAGGGAGTCTGTA-
3', the antisense primer was 5'-AAAGCAGCAGAGTGCA-
GAGAGACAG-3'; the sense primer for 24A-A was 5'-
GCTTGATGGGGACATAACCGATAGC-3', the antisense
primer was 5'-CATTGAAGGAGAATACCCAAGTATGC-3'.
One μg of total RNA was used to synthesize the first strand
of cDNA using superscript II (Gibco). The PCR amplifica-
tion was carried out in 25 μl of reaction volume contain-
ing 0.5 μl of reverse transcriptional products of total RNA
from various tissues as the template, 1×PCR buffer, 1.5
mM MgCl2, 200 mM dNTPs, 0.5 μM primer, and 1 unit of
Taq polymerase. After a 4 min denaturation at 94°C, PCR
was performed for 28 cycles. Each cycle consisted of 94°C
for 30 s, 60°C for 30 s and 72°C for 1 min, followed by a
72°C elongation for 6 min. Five μl of each PCR product
was electrophoresised on a 1% agarose gel. GAPDH was
amplified as the control with the same templates. The
upstream/downstream primers of GAPDH were 5'-GAC-
CACAGTCCATGCCATC-3'/5'-ACCAGG AAATGAGCTT-
GACA-3'.
Histochemistry and immunohistochemistry
Cryosections, 10 μm thick, were stained with hematoxylin
and eosin (H & E) according to routine protocol. Dys-
trophin and Emerin were analyzed by immunohisto-
chemistry with the goat polyclonal antibody against the
C-terminals of dystrophin (Santa Cruz) and Emerin
(Santa Cruz), respectively, and endogenous peroxidase
activity was blocked with 3% H2O2 for 15 min. Sections
were incubated in primary antibodies (1:100) overnight
at 4°C, then incubated with anti-goat IgG-HRP (1:100,
Santa Cruz) for 1 hour, followed by staining with diami-
nobenzidine for 5 min at room temperature. Lastly the
sections were counterstained with hematoxylin.
Antibodies and Western blot
Antibodies against Dysferlin (E20), α-Sarcoglycan (D-20),
β-Sarcoglycan (A-17), γ-Sarcoglycan (D-18), α-Tubulin,
and horseradish peroxidase (HRP)-conjugated second
antibodies were from Santa Cruz Biotechnology. For pro-
tein extraction from tissues, 100 mg of tissue was rapidly
homogenized in 0.5 mL of homogenization buffer [50
mmol/L Tris-HCl (pH 7.5), 150 mmol/L NaCl, 0.5%
NP40, 50 mmol/L NaF, 1 mmol/L Na3VO4, 5 mmol/L h-
glycerophosphate, m1 mmol/L DTT, 1 mmol/L phenyl-
methylsulfonyl fluoride] and the lysate was clarified by
centrifugation at 14,000 × g for 20 minutes. Boiled sam-Journal of Translational Medicine 2006, 4:53 http://www.translational-medicine.com/content/4/1/53
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ples with 2 × SDS loading buffer were loaded onto poly-
acrylamide gel (8% for α-,  β-,  γ-sarcoglycan, 7% for
dysferlin detection). After electrophoresis, the proteins
were transferred onto polyvinylidene difluoride mem-
brane (PALL). The protein blots were blocked with 10%
milk in TBST buffer for 1 hour, and then incubated for
another 1 hour at room temperature with primary anti-
body (1:1000 dilutions with 5% milk). The secondary
antibody used in the immunoblot was a 1:2,000 dilution
of HRP-linked anti-immunoglobulin G (IgG). The
enhanced chemiluminescence reagent (Amersham Bio-
sciences) was used as the substrate for detection and the
membrane was exposed to an X-ray film for visualization.
Results
Clinical data about the patients from a consanguineous 
Chinese AR-LGMD family
Here we report a consanguineous Chinese AR-LGMD fam-
ily with three affected sisters (fig. 1). The patients' mother
(III-2) married two times and the children born from her
first marriage were all normal. However, her second mar-
riage was to her cousin and three daughters (IV-5, IV-7, IV-
8) of five children suffered muscular weakness and dystro-
phy. The patients' mother (III-2) died of a stroke at the age
of 61. The children from two of the patients are healthy at
ages twelve and five, respectively (V-1, V-2). The consan-
guineous marriage and the horizontal pedigree pattern
A consanguineous Chinese AR-LGMD family with three affected sisters Figure 1
A consanguineous Chinese AR-LGMD family with three affected sisters.
Table 1: Summary of the clinical data of three patients
Physical and clinical examination Clinical symptoms or indications
Physical development Normal
Psychological development Normal
Age onset Two sisters in the second decade, the oldest in the third decade
First symptoms Difficulty in climbing stairs and standing up from chair
Pattern of muscle involvement Lower and upper limb-girdle muscle
Clinical course Slow
Pseudohypertrophy of calf Transient calf hypertrophy at early stage
cardiomyopathy No
Serum creatine kinase (SCK) Very high, approximately 10 times than normal
EMG Myopathic damage
Muscle biopsy Typical muscle dystrophic changeJournal of Translational Medicine 2006, 4:53 http://www.translational-medicine.com/content/4/1/53
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suggest that they suffer from a recessive genetic disease
and that their unaffected parents are heterozygous carri-
ers.
The affected three sisters did not complain of muscle
weakness until adolescence. The clinical data are summa-
rized in table 1. The onset occurred during the late second
decade of their lives. All patients had muscle weakness,
predominantly in the pelvic and shoulder girdle muscula-
tures, and were not ambulant by themselves at the time of
the muscle biopsy. Two of them also showed mild hyper-
trophy of the gastrocnemius muscles. The serum CK levels
of three patients were 2113.0 U/L, 2203.0 U/L, and
3000.0 U/L, respectively, which were approximately ten
times higher than the normal SCK level (24~200 U/L).
Electromyography (EMG) indicated that the pathological
changes were due to myopathic rather than neurogenic
damage. The morphological alterations of muscle biopsy
(quadriceps femoris) observed by HE staining showed the
typical dystrophic changes (Fig. 2A). None of patients had
cardiac failure, involvement of the respiratory, oculopha-
ryngeal or gastrocnemius muscle atrophy. In addition, the
possibility of the patients suffering from BMD/DMD or
EDMD was ruled out by immunohistochemical analyses
of dystrophin and emerin proteins, which were detected
on the sarcolema and nuclear membranes in the patients'
samples (Fig. 2B,2C). Taken together, our data suggest
that the three patients from this family suffer the auto-
somal recessive LGMD (AR-LGMD).
Molecular diagnosis of AR-LGMD patient
There are at least ten subtypes of AR-LGMD, named
LGMD2A to LGMD2J. Genes involved in LGMD2A-2J are
calpain 3, dysferlin, γ-, α-, β-, δ-sarcoglycans, telethonin,
trim32, fukutin related protein, and titin. We sequenced
two genes associated with AR-LGMD (calpain3 and tele-
thonin), but no mutations of those two genes were
detected in the patients, thus excluding LGMD2A and
LGMD2G. Then we detected the expressions of γ-, α-, β-
sarcoglycan and dysferlin proteins in the muscles of the
patient (IV-7) by Western blot. The results (Fig. 3) showed
the normal expressions of γ-, α-, β-sarcoglycan and dysfer-
lin proteins in the muscles of the patient (IV-7), thus
LGMD2B-LGMD2E should be excluded.
Histochemical and immunohistochemical staining in muscle biopsies from AR-LGMD patients Figure 2
Histochemical and immunohistochemical staining in muscle biopsies from AR-LGMD patients. Hematoxylin and eosin (H&E) 
staining (panel A), dystrophin expression (panel B), and emerin detection (panel C).Journal of Translational Medicine 2006, 4:53 http://www.translational-medicine.com/content/4/1/53
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Differential gene expression pattern between the relative 
normal and the dystrophic muscle from the same LGMD 
patient
For identifying additional genes involved in the patho-
genesis of AR-LGMD, the DD-RT-PCR was performed
with RNAs isolated from relative normal (deltoid) and
dystrophic skeletal muscle biopsies (quadriceps femoris)
from the same patient (IV-7). Three anchored primers in
combination with ten arbitrary primers (thirty primer
pairs in total) were used in our experiments. Results from
Fig. 4A showed an example of the differentially displayed
polyacrylamide gels, and sixty differentially expressed
bands were recovered from these gels for further sequence
analysis. Among these sequenced cDNA fragments, there
were 31 known genes, whereas the other 15 ESTs
belonged to 12 unknown genes (table 2). According to the
gene functions, the differentially expressed genes
obtained from our DD-PCR were classified into several
groups, including muscle developmental and structural
proteins, ion channels, energy metabolisms, signal trans-
duction and regulators (table 2).
The differential expression of 14 genes was confirmed by
real time qRT-PCR (table 3 and Fig. 4B). Our data demon-
strated that the genes encoding structural proteins of skel-
etal muscle fibers (titin, myosin heavy and light chains,
and nebulin) were dramatically downregulated in dys-
trophic muscles compared to the relative normal muscles,
which was consistent with previously published data [9].
These results further confirmed that the integrity of skele-
tal muscles consisting of those cellular structural proteins
play very important roles in maintaining the physiologi-
cal functions of the skeletal muscles. However, these
results were different from previously reported gene
expression profiling in DMD patients[10,11], suggesting
that different molecular mechanisms are most likely
involved in the pathogenesis of this unique type of mus-
cular dystrophy. Interestingly, we have provided experi-
mental evidence to show that the genes encoding the
proteins involved in signal transduction and gene expres-
sion regulation [reticulocalbin 1, kinectin 1, fatty acid
desaturase 1, IGFBP5, Nedd4 family interacting protein 1
(NDFIP1), and SMARCA2 (SWI/SNF related, matrix asso-
ciated, actin dependent regulator of chromatin, subfamily
a, member 2)] were up-regulated in the dystrophic mus-
cles. These results suggest that the pathogenesis develop-
ment of LGMD is a complicated process and further
analysis of the function of these genes in the pathogenesis
of LGMD might provide valuable mechanistic informa-
tion for understanding the molecular mechanism of
LGMD development. Additionally, the functional investi-
gation of those differentially expressed unknown genes
could offer new information for revealing the pathogene-
sis of LGMD.
Tissue specific expression patterns of several differentially 
expressed unknown genes
The semi-quantitative RT-PCR method was used to vali-
date the differential expression of these unknown genes
between the relative normal and dystrophic tissues. Total
RNAs were isolated from the relative normal and patho-
logical skeletal muscle tissues, and the amount of mRNA
was normalized equally by the internal control, G3PDH.
The primers were designed specifically for 6 new ESTs (A1,
5A-C, 11A-A, 7B-B, 2A-A, 24A-A) as indicated in the Mate-
rials and methods. The results indicated that the expres-
sion of A1 and 5A-C were up-regulated while 7B-B and
2A-A were down-regulated in the dystrophic skeletal mus-
cle. There were no obvious expression changes of the ESTs
11A-A and 24A-A observed (fig. 5).
For more functional information of these three differen-
tially expressed unknown genes, the tissue distributions of
the mRNAs were determined by RT-PCR. Total RNAs were
isolated from various tissues of normal people, including
the testes, liver, heart, quadriceps, intestine, kidney,
spleen, pancreas, lung, and brain. The results indicated
that 2A-A was mainly expressed in cardiac and skeletal
muscles (Fig. 6), and as shown in Fig 5, 2A-A was down-
regulated in the dystrophic skeletal muscle, these findings
suggest that 2A-A may play important roles in skeletal
muscle development and the pathogenesis of LGMD. The
mRNA of A1 and 7B-B was detected in all the tested tissues
(Fig. 6). Interestingly, although the expression level of A1
was low in the skeletal muscle of the normal person, it was
The expression analyses of α-, β-, γ-sarcoglycan and dysferlin  protein in the muscles of patient by Western blot Figure 3
The expression analyses of α-, β-, γ-sarcoglycan and dysferlin 
protein in the muscles of patient by Western blot. The total 
proteins extracted from skeletal muscles of normal person 
(lane 1), relative normal muscle biopsies of patient IV-7 (lane 
2), and dystrophic muscle biopsies of patient IV-7 (lane 3).Journal of Translational Medicine 2006, 4:53 http://www.translational-medicine.com/content/4/1/53
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Table 2: Differentially expressed genes between relative normal and dystrophic muscles from the same AR-LGMD patient
Accession 
no.
Gene title (gene symbol) Gene expression pattern in dystrophic muscle
Muscle development and function
NM_133437 Titin (TTN), transcript variant novex-2 Down
NM_002470 Myosin, heavy polypeptide 3, skeletal muscle, embryonic (MYH3) Down
NM_000257 Myosin, heavy polypeptide 7, cardiac muscle, beta (MYH7) Down
NM_000432 Myosin, light polypeptide 2, regulatory, cardiac, slow (MYL2) Down
NM_194293 Cardiomyopathy associated 1 (CMYA1) Down
NM_004543 Nebulin Down
NM_006175 Nebulin-related anchoring protein (NRAP), transcript variant 1 Down
Ion homeostasis
NM_003374 Voltage-dependent anion channel 1 Down
Energy metabolism
NM_002612 Pyruvate dehydrogenase kinase, isoenzyme 4 (PDK4) Down
NC_001807 NADH dehydrogenase subunit 2 Down
NM_013402 Fatty acid desaturase 1 (FADS1) Up
Signal transduction and regulator
NM_182926 Kinectin 1 (Kinesin receptor) Up
NM_002901 Reticulocalbin1, EF hand calcium binding domain Up
NM_014365 Heat shock 22 kDa protein 8 (HSPB8) Down
NM_206876 Protein phosphatase 1, catalytic subunit, beta isoform Down
NM_030937 Cyclin L2 (CCNL2) Down
NM_014001 ADP-ribosylation factor binding protein GGA3 Down
NM_003566 Early endosome antigen 1 Up
NM_030571 Nedd4 family interacting protein 1 (NDFIP1) Up
NM_000599 Insulin-like growth factor binding protein 5 (IGFBP5) Up
NM_003916 Adaptor-related protein complex 1, sigma 2 subunit Down
Regulator for gene expression and protein translation
NM_139045 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 
(SMARCA2), transcript variant 2
Up
NM_012433 Splicing factor 3b, subunit 1, 155 kDa (SF3B1) Up
NM_014752 Signal peptidase complex subunit 2 homolog (S. cerevisiae) (SPCS2), mRNA Down
NM_001006 Ribosomal protein S3A (RPS3A) Down
Others
NM_020384 CLDN2 gene for claudin 2 Down
NM_016056 Transmembrane BAX inhibitor motif containing 4 Down
AF168681 CRIM1 protein gene, partial cds; and FEZ2 gene Up
NM_0010179
77
IQ motif and WD repeats 1 (IQWD1), transcript variant 2 Down
BK001418 Metastasis associated in lung adenocarcinoma transcript 1 long isoform, transcribed non-coding RNA Up
AF268386 DPDP-3 dental pulp-derived protein 3 Down
Unknown genes
DW009597 3A-B Down
EC268059 5A-C Up
EC268060 24A-A Down
EC268061 5A-D Down
EC268062 7B-B Down
EC268063 2A-A Down
EC268064 18B-C Up
EC268065 29B-A Up
EC268066 25A-A Down
EC268067 23A-C Down
EC268068 29A-C Down
EC268069 A1 UpJournal of Translational Medicine 2006, 4:53 http://www.translational-medicine.com/content/4/1/53
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A typical sequencing gel (panel A, the arrows indicate the differentially expressed bands), real time qRT-PCR validation (panel  B) Figure 4
A typical sequencing gel (panel A, the arrows indicate the differentially expressed bands), real time qRT-PCR validation (panel 
B). The relative normal muscle (A) and the dystrophic muscle (B).Journal of Translational Medicine 2006, 4:53 http://www.translational-medicine.com/content/4/1/53
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up-regulated greatly in pathological skeletal muscles (fig.
5), indicating that overexpression of A1 may have a func-
tional role in the pathogenesis of muscular dystrophy.
Discussion
Limb-girdle muscular dystrophy (LGMD), a kind of pro-
gressive muscular dystrophy (PMD), is a group of hetero-
geneous disorders with variable clinical and genetic
features including autosomal dominant and recessive
subgroups [12], in which the pelvic and shoulder girdle
musculatures are predominantly or primarily involved.
This kind of disease is also characterized by increased SCK
levels, muscle fiber necrosis, and regeneration [13].
LGMD varies greatly from patient to patient in the age of
onset, in disease progression and in the distribution of the
affected muscles [14]. At least 13 genes, 3 autosomal dom-
inant and 10 autosomal recessive, responsible for LGMDs
have been identified [7,8]. Genotype-phenotype associa-
tions have been studied for the different types of LGMD in
an attempt to promote our comprehension of its underly-
ing pathological mechanisms. However, from the pub-
lished information about the functions of those 13 genes,
it is difficult to interpret the pathogenesis of the LGMDs'
complex phenotype. Therefore, searching for the LGMD
related genes and investigating their functions associated
with disease development is still necessary, not only for a
better understanding of the pathogenesis of LGMDs but
also for the molecular diagnosis of LGMDs in a clinical
setting.
In this study, we reported a Chinese family with three sis-
ters suffering from AR-LGMD. In order to identify the
genes associated with the pathogenesis of AR-LGMD, DD-
RT-PCR was used to compare the gene expression differ-
ences between the relative normal and dystrophic skeletal
muscles from the same LGMD patient, thereby search for
candidate genes involved in the pathogenesis of AR-
LGMD. We have found that 31 known genes and 12 new
ESTs were differentially expressed between the normal
and dystrophic tissues and that the differentially
expressed known genes include structural proteins, anion
channels, enzymes and signal transduction molecules.
From our experimental data, the expression levels of
many genes, which encode for structural proteins of skel-
etal muscle fiber (such as MYH3, MYH7, MYL2, titin, neb-
ulin related anchoring protein, and voltage-anion
channel), were dramatically decreased in the dystrophic
muscles compared to the relative normal tissues. Myosins
are a large family of protein motors that contain at least 18
different classes [15]. They interact with actin filaments to
generate a broad spectrum of eukaryotic cell movements
that include phagocytosis, vesicle transport, cytokinesis
and maintenance of cell shape in addition to their well-
known role in muscle contraction [16,17]. Titin is a giant
filamentous protein that forms a separate myofilament
system in both skeletal and cardiac muscles. Titin has its
NH2 terminus embedded in the Z-band and extends with
its COOH terminus localized in the middle (M-band) of
Table 3: The differential expressions of 14 genes were confirmed by real time qRT-PCR
No Gene name Primers for real-time qRT-PCR Fold change
1 Nebulin-related anchoring protein (NRAP), transcript variant 1 F: 5'-GCCTCAGGCATGCTCAGAAG-3'
R: 5'-ACTTTGTAGGAGCCAGGAGGG-3'
-76.92
2 Reticulocalbin1, EF hand calcium binding domain F: 5'-GAAACCCTGGAGGACATCGA-3'
R: 5'-TCTGGCTCAGGGCCATTCT-3'
1.99
3 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, 
member 2 (SMARCA2), transcript variant 2
F: 5'-CATGCTTCTCTGTCACAACGC-3'
R: 5'-TCTGCCGGGCACTCTTAAAC-3'
2.02
4 Fatty acid desaturase 1 (FADS1) F: 5'-CCTTGTGTGCCAAGCATGG-3'
R: 5'-TAGCCAGAGCTGCCCTGACT-3'
45.34
5 Voltage-dependent anion channel 1 F: 5'-CAAAATCCCGAGTGACCCAG-3'
R: 5'-GGAGCCGCCAAACTCTGTC-3'
-5.65
6 Kinectin 1 (Kinesin receptor) F: 5'-TTCCCCAGAAACGGAGTCTTC-3'
R: 5'-TGAGCTGTTGGTTTACCGCC-3'
1.16
7 Cardiomyopathy associated 1 (CMYA1) F:5'-CACTGCCCCAGGACTGAAGT-3'
R:5'-AAAGGGAAATGGCCCACAGTA-3'
-25
8 Insulin-like growth factor binding protein 5 (IGFBP5) F: 5'-TGTACCTGCCCAATTGTGACC-3'
R: 5'-CGTACTTGTCCACGCACCAG-3'
1.56
9 Myosin, heavy polypeptide 3, skeletal muscle, embryonic (MYH3) F: 5'-ACGGTGAAGGACCTGCAGC-3'
R: 5'-CAGCTCTCGGATCCTGGTCTC-3'
-8.77
10 Myosin, heavy polypeptide 7, cardiac muscle, beta (MYH7) F: 5'-CAGAAGCGCAACGCAGAGT-3'
R: 5'-CGCAGCAGGTTTTTCCTGTC-3'
-25
11 Myosin, light polypeptide 2, regulatory, cardiac, slow (MYL2) F:5'-GAAACTTAAGGGAGCGGACCC-3'
R:5'-GCATTTCCCGAACGTAATCAG-3'
-20.41
12 Nedd4 family interacting protein 1 (NDFIP1) F: 5'-CCTGACCACTTCAGCTGCAG-3'
R:5'-CAGGGAAATAGGTGGAAAACCTG-3'
2.15
13 Ribosomal protein S3A (RPS3A) F: 5'-CCTGACCACTTCAGCTGCAG-3'
R:5'-CAGGGAAATAGGTGGAAAACCTG-3'
-3.78
14 Titin (TTN), transcript variant novex-2 F: 5'-CAAAAATTTCCGTGGCCAGT-3'
R:5'-GTGTCACCACTTGTTCTCAATACTACC-3'
-43.48
15 glyceraldehyde-3-phosphate dehydrogenase, G3PDH F: 5'-CAACTGCTTAGCACCCCTGG-3'
R: 5'-CAGTCTTCTGGGTGGCAGTGA-3'
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the aligned myosin filaments (A-band) [18,19]. The inter-
action of myosin, actin and titin play important roles in
muscle contraction. Therefore, the expression alterations
of these genes could directly affect the development and
pathological changes of skeletal muscles, thus being
implicated in the pathogenesis of muscular dystrophy.
We also found some differentially expressed transcripts
encoding protein enzymes involved in protein synthesis
and modification, energy metabolism, and gene expres-
sion regulation. The gene expression of the catalytic subu-
nit (beta isoform) of PP1 was down-regulated in
dystrophic muscles compared to the relative normal mus-
cle. Protein phosphatase-1 (PP1) is 1 of 4 major serine/
threonine-specific protein phosphatases involved in the
dephosphorylation of a variety of proteins. Therefore PP1
plays a key role in numerous biological processes such as
glycogen metabolism, cell cycle regulation, smooth mus-
cle contractions, and protein synthesis [20,21]. We found
that the expression level of voltage-dependent anion
Confirmation of the differential expression of several unknown ESTs between the relative normal and dystrophic muscle tis- sues by semi-quantitative RT-PCR Figure 5
Confirmation of the differential expression of several unknown ESTs between the relative normal and dystrophic muscle tis-
sues by semi-quantitative RT-PCR. The relative normal muscle (A) and the dystrophic muscle (B).Journal of Translational Medicine 2006, 4:53 http://www.translational-medicine.com/content/4/1/53
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channels (VDAC) was decreased in dystrophic muscle
compared to the relative normal muscle. VDACs are abun-
dant 30-kDa mitochondrial outer membrane proteins
found in all eukaryotes serving as a binding site for
cytosolic hexokinase, providing the enzyme with prefer-
ential access to the ATP derived from oxidative phosphor-
ylation [22,23]. Energy metabolism and skeletal muscle
contraction cannot be carried out without VDACs.
Although the expression alteration of these genes could
have a close relationship with LGMD disease, their func-
tional roles in the pathogenesis of LGMD need to be fur-
ther investigated.
The altered expression of 6 new ESTs in the dystrophic
muscles has been confirmed by the semi-quantitative RT-
PCR method, and their tissue specific expression patterns
were analyzed by RT-PCR. The results showed that the
mRNA level of two ESTs (A1 and 5A-C) were up regulated
in the dystrophic skeletal muscle, whereas two of them
(7B-B and 2A-A) were down regulated. The tissue distribu-
tion and altered expression pattern of these ESTs provide
important clues for understanding their function in the
skeletal muscle development and pathogenesis of
LGMDs. Although the expression level of A1 is very low in
the skeletal muscle of the normal person, it is up-regu-
lated in pathological skeletal muscles. Thus, the changes
in A1 expression have a close relationship with the patho-
genesis of muscular dystrophy. Abundant expression of
2A-A mRNA was mainly detected in cardiac and skeletal
muscles. It might also be of some interest to further inves-
tigate the role of transcripts whose functions are still
unknown.
Conclusion
In summary, the functional analysis of these expression-
altered genes in the pathogenesis of LGMD could provide
additional information for understanding possible
molecular mechanisms of LGMD development.
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